Skip to main content

Advertisement

Table 5 Impact of ICS inhaler device switch: outcome measures for switched vs. control patients during the year after the switch

From: Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control

Outcome Measure   Switched Cohort (n = 824) Control Cohort (n = 824) p Value For Comparison
Oral corticosteroid courses/yr, n (%) 0 698 (85%) 721 (88%) 0.197†
  1 80 (10%) 65 (8%)  
  2 23 (3%) 12 (1%)  
  3–11 23 (3%) 26 (3%)  
Hospitalized for asthma, n (%)   3 (0.04%) 14 (1.70%) NS
SABA daily dose,* median (IQR)   0.82 (0.27–2.19) 0.55 (0–1.64) <0.001 §
Asthma consultation rate, n (%) 0 569 (69%) 514 (62%) 0.135†
  1 155 (19%) 177 (21%)  
  ≥ 2 100 (12%) 133 (16%)  
  1. ICS = inhaled corticosteroid; IQR = interquartile range; NS = not significant; SABA = short-acting β-agonist
  2. *One dose of SABA was defined as salbutamol 200 μg or terbutaline 500 μg.
  3. †χ2 test, §Mann-Whitney